Merck achieved positive outcomes from two Phase III trials of its oral PCSK9 inhibitor enlicitide decanoate, demonstrating significant LDL cholesterol reductions in hyperlipidemia patients. Concurrently, the FDA approved Merck's monoclonal antibody Enflonsia for preventing RSV lower respiratory disease in infants, positioning it directly against Sanofi-AstraZeneca's Beyfortus. These advancements arrive amid uncertainty due to the recent overhaul of the CDC's vaccine advisory committee, which may affect upcoming recommendation processes and market dynamics.